BI 655064
Alternative Names: BI-655064Latest Information Update: 09 Aug 2021
At a glance
- Originator Boehringer Ingelheim
- Class Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lupus nephritis
- No development reported Idiopathic thrombocytopenic purpura; Rheumatoid arthritis
Most Recent Events
- 27 Jul 2021 Boehringer Ingelheim completes a phase II trial for Lupus nephritis (Adjunctive treatment) in Greece, Australia, Canada, Czech Republic, France, Germany, Hong Kong, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Portugal, South Korea, Spain, Thailand, United Kingdom and the US (SC) (EudraCT2017-003101-17) (NCT03385564)
- 02 Jun 2021 Efficacy and adverse events data from a phase II trial in Lupus nephritis presented at the 22nd Annual Congress of the European League Against Rheumatism (EULAR-2021)
- 18 Aug 2020 Boehringer Ingelheim completes a phase-II clinical trial in Lupus nephritis (Adjunctive treatment) in USA, Australia, Austria, Canada, Czech Republic, France, Germany, Greece, Hong Kong, Italy, Japan, South Korea, Malaysia, Mexico, Philippines, Portugal, Spain, Turkey, Thailand, Poland, Serbia and the UK (SC) (NCT02770170)